Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. - Wikidata - wikimedia - TriplyDB

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

http://www.wikidata.org/entity/Q37624276

about

Targeted immunotherapy for pediatric solid tumors Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies Immunotherapy of Childhood Sarcomas Osteosarcoma: Current Treatment and a Collaborative Pathway to Success Adoptive cell therapy for sarcoma Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma.Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Future directions in the treatment of osteosarcoma.Advances in therapy for pediatric sarcomas.Immune-based therapies for childhood cancer.Advances in emerging drugs for osteosarcoma.Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Novel insights and therapeutic interventions for pediatric osteosarcoma.Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.Progress and opportunities for immune therapeutics in osteosarcoma.Drugs in early clinical development for the treatment of osteosarcoma.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma.Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.Current and future therapeutic approaches for osteosarcoma.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.

P2860

Q26747703-FA46849E-D62D-4DBE-93BC-7AC922B87C1C Q26782646-BEE04525-6D6C-45E8-8C97-0BA8502BBC0A Q26795369-B2F4C097-704C-4E15-B60B-B895B2C9D943 Q26797555-BC1622D8-FCD2-448D-B181-6EAE1E30A2BE Q27009541-B47A4C0C-604F-452E-A2B4-8A749806E55A Q35030373-F5552D79-DEEB-4371-963D-1EED504F7670 Q35146479-91BBDF28-52E3-478E-BDCC-650B8A3FB1A5 Q35598804-F4F8DF2E-5A9E-432C-A023-AD97D5E42A40 Q36133953-02C84F47-617C-4AD0-8EE7-F5B73A21A625 Q36157472-0A4486B4-70CF-4AC7-9E20-C15DE5E50499 Q36261159-6CB193A2-1EA2-4561-AC4D-0856596C5537 Q36600800-D239257B-B14F-40FB-85E7-B7837BD39650 Q38217354-63DCF8C3-88E3-41CC-A59C-989492B46168 Q38263108-1196A327-D23D-4D2A-BEF3-C26F374A22AB Q38506118-DAFA78EB-F29A-472F-A69F-A2B9B1DE99EA Q38708792-D00B88AB-069E-4EC3-9BD6-B46E2AB8E9B4 Q38783252-03026238-014B-4CBC-8EDC-31BC56B553C3 Q38819276-43AEA565-AF29-426A-B08F-03989B860D94 Q38840985-3010C910-11BB-4497-BF87-2AD3E1C30FE6 Q38948905-ED025249-76DE-47CB-AD10-09A7A4855C64 Q38955517-F246B0D2-D0F4-46CC-BBFD-31BCF986958B Q39229404-D1DA2DCF-11B2-418F-9619-D94A404D1880 Q39401628-4914194A-D987-4375-A447-E46CD6930BAE Q40137306-6E51AE74-EFD4-40CF-B131-0E6504DC65BF Q40700335-EED7A263-BFAB-4F07-A054-EFC30259D317 Q41636566-D8CBCA27-F196-449D-A118-02FA12C2B589 Q42576424-26725FAC-D4B2-4F7D-A9E3-91C36AB7CE4A Q47118215-9C0EA893-5763-4CC4-87B5-B11C54104522 Q47360357-455448DD-B72F-4A4D-AF09-35DD627B1787 Q47832898-4BE2A2BC-CDD7-4688-A5DF-D5D5CFA004EB Q49210694-C285E9C2-741E-4DF8-A46D-84C41F7C1333 Q51039603-3EFD2F86-0A54-4CF2-B6CE-30545EC337AC Q51779979-8D727F3E-1A76-47B2-8CA6-9BF0C1359873

P2860

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.

http://www.wikidata.org/entity/Q37624276

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@en

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@nl

type

label

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@en

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@nl

prefLabel

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@en

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.

@nl

P1433

Q37624276-29D13093-D4CF-4E5D-B29F-81BD3F0D3615

P1476

Q37624276-13FF3391-6A44-4937-8B87-821D61A022CF

P2093

Q37624276-0A3991C3-AAA9-4DE1-8176-6EEF746BC909

Q37624276-14E224AA-9D68-4233-BC9F-E320CE1E4B1F

Q37624276-3F418286-375E-4071-B385-1D187ADFF5A1

Q37624276-3F8CE01B-6C21-4A43-B8F1-95898F1AF4D2

Q37624276-4B6A987E-B2E2-420C-AF62-B3809223D7C5

Q37624276-B635FB52-5BBC-4D67-81B5-572059EB61DA

Q37624276-F9B4DCCD-B4DB-4801-AE50-A76BCDE8CDE7

P2860

Q37624276-05DE232A-DFDC-4D41-9C89-69F7A92E010A

Q37624276-05F7B7D1-930C-42A5-B7EC-F27529976EF1

Q37624276-085F9ADE-9D63-40AC-A2F8-4D74E3739226

Q37624276-181521CB-CC26-41D9-B83D-338A1A6C58A5

Q37624276-1D8D5902-5B16-4079-9A72-2C4DDC9EE7EE

Q37624276-227AA204-A142-4D91-808F-8F6DBE59DC7F

Q37624276-28B9799C-B278-4458-8AAE-C94D7554A7E6

Q37624276-2FA23331-21E5-48EF-A319-018B761D2380

Q37624276-5137B5C0-3D75-48B1-B951-CFDACED9E15A

Q37624276-62B580C1-218D-4FC3-9E9D-CA3F84D62F2A

P304

Q37624276-59B73746-781D-430E-A9CE-D4A07DEE7B17

P31

Q37624276-6368568F-616A-45D5-9779-5AC06695781D

P356

Q37624276-67E0395D-E4A7-439E-97EA-D27CB7FD6141

P407

Q37624276-0B5EE695-4D4D-4B25-A901-9C85F9729BE0

P433

Q37624276-6860CE6B-0553-4237-BD13-FFD962C75049

P478

Q37624276-756E9917-1059-4320-84A5-F25976F0E6ED

P50

Q37624276-FBB10C6D-E274-4CBD-AF27-979B6D17F5B5

P577

Q37624276-080B8B35-DA95-43FD-B20D-533536E12EC4

P698

Q37624276-71FABB8D-8E8B-438E-97A2-813E887B149E

P921

Q37624276-54FBC1EE-CB14-4532-A2F4-D393167A8EC3

Q37624276-734C172C-22E9-4754-81E9-078305550776

P932

Q37624276-A8B0AF4E-E559-401C-B7D3-79C5AC1BCBC3

P356

P1433

P1476

Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma

@en

P2093

David Geller

http://www.w3.org/2001/XMLSchema#string

John Tarim

http://www.w3.org/2001/XMLSchema#string

Jonathan Gill

http://www.w3.org/2001/XMLSchema#string

Marissa Linkowski

http://www.w3.org/2001/XMLSchema#string

Michael Roth

http://www.w3.org/2001/XMLSchema#string

Rebecca Sowers

http://www.w3.org/2001/XMLSchema#string

Sajida Piperdi

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

P304

548-554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28461

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24166473

http://www.w3.org/2001/XMLSchema#string

P921

P932

3946333

http://www.w3.org/2001/XMLSchema#string